Legacy Housing Corp has announced the appointment of Darren McCallon as its new Chief Financial Officer (CFO), effective November 9, 2026. This strategic move comes as the company seeks to bolster its financial operations and leadership.
McCallon, age 55, is a seasoned executive with over 25 years of experience in financial reporting, accounting operations, capital planning, mergers and acquisitions, and strategic finance. His previous roles include serving as CFO of Fortune Insurance, where he led a successful sale to OneDigital, and as CFO of 4WEB Medical, an orthopedic implant company.
“We are excited to welcome Darren to our team,” said Kenneth E. Shipley, CEO of Legacy Housing. “His extensive background in finance and operations will be invaluable as we continue to grow and navigate the competitive landscape of the mobile homes industry.”
Background
Legacy Housing Corp, incorporated in Texas, operates within the mobile homes sector, classified under SIC code 2451. The company trades on the Nasdaq under the ticker symbol LEGH. Legacy Housing focuses on manufacturing and selling manufactured homes and related products.
What the Filing Says
According to the SEC filing, McCallon replaces Jon Langbert, who has resumed his retirement. The company and McCallon expect to enter into an employment agreement following his appointment. The filing states, “Mr. McCallon brings extensive experience in financial management across various industries.”
Impact
This leadership change may affect various stakeholders, including employees, investors, and customers. With McCallon's experience in finance and strategic planning, the company aims to enhance its operational efficiency and financial performance, potentially benefiting its market position.
What's Next
The filing does not say what happens next.
Read Next
Alps Group Regains Compliance with Nasdaq Listing Standards
Ainos, Inc. Receives Nasdaq Delisting Notice Over Equity
Compass Therapeutics Receives Nasdaq Deficiency Notice
60 Degrees Pharmaceuticals Faces Nasdaq Delisting Risk
Biofrontera Inc. Faces Nasdaq Delisting Due to Low Stock Price
Senti Biosciences dismisses KPMG, appoints new auditor KNAV










